A5044752358- Food Allergy and Anaphylaxis Research
- Asthma and respiratory diseases
- Allergic Rhinitis and Sensitization
- Eosinophilic Esophagitis
- Respiratory and Cough-Related Research
- Pharmaceutical studies and practices
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- COVID-19 Clinical Research Studies
- Contact Dermatitis and Allergies
- Mast cells and histamine
- Long-Term Effects of COVID-19
- Urticaria and Related Conditions
- Immunodeficiency and Autoimmune Disorders
- Cystic Fibrosis Research Advances
- SARS-CoV-2 and COVID-19 Research
- Inhalation and Respiratory Drug Delivery
- Iron Metabolism and Disorders
- Chronic Obstructive Pulmonary Disease (COPD) Research
Hospital Clínic de Barcelona
2024-2025
Universitat de Barcelona
2024
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2024
Hospital Universitario La Paz
2021-2023
Centre for Biomedical Network Research on Rare Diseases
2023
Hospital La Paz Institute for Health Research
2023
To assess the safety of biological therapy for severe T2 asthma (omalizumab, mepolizumab, benralizumab and reslizumab) under real-life conditions in elderly patients older than 70 years.Retrospective data collection including clinical characteristics, comorbidities, treatment, disease control adverse events (AE) all with on years seen Severe Asthma Unit our hospital.Of 147 being treated biologics, 21 were included. The median age these was 76.3 (range 71-86) majority women (n = 18, 85.7%)....
Biologics have revolutionized the treatment of many diseases. In this regard, omalizumab (OMA), an anti-IgE monoclonal antibody, is recommended therapeutic option for patients with chronic spontaneous urticaria (CSU) refractory to second-generation H1-antihistamines. Several studies confirm efficacy and safety drug. However, literature focusing on elderly population scarce, as age group often excluded from clinical trials. Therefore, pharmacological CSU in a challenge that increased by their...
Background: The prevalence of cardiovascular events (CVEs) in patients with asthma varies amongst studies, little evidence as to their treated monoclonal antibodies (mAbs). In this retrospective, observational study, we aimed evaluate the CVEs T2 and non-T2 identify risk factors associated CVEs. Methods: A total 206 severe were included. Demographic variables, respiratory comorbidities collected, along function, laboratory parameters pharmacotherapy, including treatment mAbs. Results: 10.7%...
Gastrointestinal symptoms, under the tip of iceberg in lipid transfer protein food allergy